ClinicalTrials.gg
CompletedNCT06921551Updated Jun 2, 2026

Exploratory Pilot Study on the Prolonged Use of the ABLE Exoskeleton in Multiple Sclerosis

An interventional study of ABLE Exoskeleton in Multiple Sclerosis, sponsored by ABLE Human Motion S.L.. Completed at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by ABLE Human Motion S.L. · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Multiple Sclerosis with a site in Spain — 35 open to participants now, 56 under way, 14 of them phase 3. Multiple Sclerosis · Spain.

Enrollment
186th of 202
19 · median 137
Started
2025
with 24 others
No phase
68 of 230
22 open now
Registered
197th of 230
by date

Among the 230 studies in Multiple Sclerosis with a site in Spain, this one is the 186th largest by enrollment of the 202 interventional ones that give a count, is one of 25 that started in 2025, is one of 68 with no phase, and was the 197th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

35 of the 230 studies in Multiple Sclerosis with a site in Spain are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Multiple Sclerosis with a site in Spain, or all of them as a file.
02

Study summary

The goal of this study is to explore the potential clinical benefits of the ABLE Exoskeleton as part of a rehabilitation program in people with multiple sclerosis. The main question it aims to answer is:

Can a rehabiliation program with the ABLE Exoskeleton help to mantain the physical and psychosocial health of people with multiple sclerosis?

Participants will:

  • Have a gait training session of 60 min with the exoskeleton once a week for 12 months at the clinic
  • Have an evaluation (tests and questionnaires) every 3 months at the clinic
03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Gait training
  • Wearable exoskeleton
  • Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 70 years old
  • Diagnosed with multiple sclerosis
  • Currently undergoing outpatient physical therapy treatment at the investigation site
  • Ability to give

Exclusion criteria

Exclusion Criteria:

  • Significant osteoporosis that may increase the risk of fracture
  • Unresolved fractures in the pelvis or extremities, or history of fragility fractures in the lower extremities in the last 2 years
  • Spinal instability (or spinal orthoses, unless authorized by a physician)
  • Severe spasticity: Level 4 on the Modified Ashworth Scale
  • Orthostatic hypotension. Inability to tolerate a minimum of 30 minutes standing
  • Uncontrolled autonomic dysreflexia
  • Medical instability
  • Unstable cardiovascular system (CVS), hemodynamic instability, untreated hypertension (SBP>140, DBP>90 mmHg), unresolved deep venous thrombosis (DVT)
  • Serious comorbidities, including any condition that a physician deems inappropriate for use of the ABLE Exoskeleton or to complete participation in the study
  • Skin integrity problems on the contact surfaces of the device or that would prevent sitting
  • Grade I or higher on EPUAP (European Pressure Ulcer Advisory Panel, 2019) on areas that will be in contact with the exoskeleton
  • Colostomy
  • Anthropometric measurements outside the values compatible with ABLE Exoskeleton. In particular, height not between 1.5-1.9 m, or weight over 100 kg
  • Anatomical constraints (such as eg length differences, users unable to position themselves inside the device) that are incompatible with the device
  • Restrictions in range of motion that prevent normal gait from being achieved or preventing the completion of a normal transition from sitting to standing or standing to sitting
  • Heterotopic ossification
  • Known pregnancy or breastfeeding
  • Cognitive impairment that results in the inability to follow simple instructions, particularly psychological or cognitive problems that do not allow a participant to follow study procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Intervention with exoskeleton

    Participants will undergo 60-min gait training sessions with the exoskeleton as part of their rehabilitation program once a week for up to 12 months

    Device: ABLE Exoskeleton

Interventions

  • DeviceABLE Exoskeleton

    Participants will undergo 60-min gait training sessions with the exoskeleton once a week for up to12 months

06

What researchers measure

Primary outcomes

  1. Number of therapeutic objectives achieved

    Two therapeutic objectives per participant will be defined at baseline. At the end of the training program, it will be assessed if the objectives were accomplished or not.

    Time frame: From baseline to the end of the training program at 12 months

  2. Lower extremity muscle strenght

    The Daniels Muscle Testing scale will be used to measure the strength of muscles in the lower extremities at baseline, every 3 months and at the end of the gait training program to assess motor function after the training. Scores range from 0 (absence of muscle activity) to 5 (normal muscle activity)

    Time frame: Baseline, 3, 6, and 12 months post-training

  3. Modified Ashworth Scale (MAS)

    The Modified Ashworth Scale (MAS) measures spasticity in patients with lesions to the central nervous system. The scale assigns a grade of spasticity from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension). It will be evaluated at baseline, every 3 months and at the end of the gait training program without the device to assess the change in the spasticity after training

    Time frame: Baseline, 3, 6, and 12 months post-training

  4. Location and level of pain

    The location and level of pain using the numeric rating scale (NRS) will be assessed at baseline, every 3 months and at the end of the gait training program to assess the reduction of pain aftr the training

    Time frame: Baseline, 3, 6, and 12 months post-training

  5. Timed 25-Feet Walk test (T25FW)

    The Timed 25-Foot Walk (T25FW) test measures the time a person needs to walk 25 feet. This test will be assessed at baseline, every 3 months, and at the end of the gait training program without the device to assess the change in the walking function after the training

    Time frame: Baseline, 3, 6, and 12 months post-training

  6. 6-Minute Walk Test (6MWT)

    The 6-Minute Walk Test (6MWT) measures the distance a person can walk in 6 minutes. This test will be assessed at baseline, every 3 months, and at the end of the gait training program without the device to assess the change in the walking function after the training

    Time frame: Baseline, 3, 6, and 12 months post-training

  7. Borg Rating of Perceived Exertion

    The Borg Rating of Perceived Exertion (RPE) scale is used to measure a person's perception of their effort and exertion, breathlessness, and fatigue during physical activity. Scores range from 6 (no exertion at all) to 20 (maximal exertion). It will be evaluated during the 6MWT at baseline, every 3 months, and after the end of the gait training program without the device to assess the change in the perceived exertion after the training

    Time frame: Baseline, 3, 6, and 12 months post-training

  8. Trunk Impairment Scale (TIS)

    The Trunk Impairment Scale (TIS) measures the motor impairment of the trunk through the evaluation of static and dynamic sitting balance as well as coordination of trunk movement. The total score ranges from 0 (minimal performance) to 23 (perfect performance). This test will be assessed at baseline, every 3 months, and at the end of the gait training program without the device to assess the change in the trunk impairment after training

    Time frame: Baseline, 3, 6, and 12 months post-training

  9. Barthel Index (BI) score

    The Barthel Index (BI) will be used to assess the participants' ability to perform mobility and self-care activities of daily living (ADL). The total score ranges from 0 (total dependency) to 100 (independency). It will be evaluated at baseline, every 3 months, and after the gait training program without the device to assess the change in the independence to perform ADL after the training

    Time frame: Baseline, 3, 6, and 12 months post-training

  10. Modified Fatigue Impact Scale (MFIS) score

    The Modified Fatigue Impact Scale (MFIS) provides an assessment of the effects of fatigue in terms of physical, cognitive, and psychosocial functioning in persons with multiple sclerosis. The total score ranges from 0 to 84, with higher scores meaning a higher impact of fatigue. It will be evaluated iat baseline, every 3 months and at the end of the gait training program without the device to assess the change in the fatigue after the training

    Time frame: Baseline, 3, 6, and 12 months post-training

  11. Multiple Sclerosis Quality of Life-54 (MSQoL-54) scores

    The Multiple Sclerosis Quality of Life-54 (MSQoL-54) is a multidimensional health-related quality of life (QoL) measure that combines both generic and MS-specific items into a single instrument. There is no single overall score for the MSQoL-54. Two summary scores - physical health and mental health - can be derived from a weighted combination of scale scores. The higher the score, the best the outcome. It will be evaluated at baseline, every 3 months and at the end of the gait training program without the device to assess the change in the QoL after the training

    Time frame: Baseline, 3, 6, and 12 months post-training

  12. Self-perceived impact on general health status

    Participants' perceptions of the impact on their general health will be evaluated by the completion of a self-report questionnaire on the perceived impact on general health. This questionnaire has been designed by the researchers and intends to identify to what extent participants feel that the ABLE Exoskeleton contributed to a change in their health. The questionnaire covers 7 categories (cardiovascular system, musculoskeletal pain, neuropathic pain, bladder and bowel, spasticity, and sleep quality) using a 7-point Likert scale to assess the change.

    Time frame: 3, 6, and 12 months post-training

  13. Level of motivation

    Participants' perceptions on the level of motivation generated by the program with the ABLE Exoskeleton will be evaluated by the completion of a self-report questionnaire using a 7-point Likert scale. This questionnaire has been designed by the researchers.

    Time frame: After 12 months post-training

  14. Psychosocial Impact of Assistive Devices Scale (PIADS) score

    The Psychosocial Impact of Assistive Devices Scale (PIADS) is a 26-item, self-reported questionnaire that provides a measure of user perception and other psychological factors associated with assistive technology devices. Scores range from -78 (maximum negative impact) to +78 (maximum positive impact). It will be used to assess the effects of the ABLE Exoskeleton on functional independence, well-being, and quality of life of participants after the training program experience

    Time frame: After 12 months post-training

  15. Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) score

    The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) is a 12-item outcome measure that assesses user satisfaction with two components (Device and Services) using a 5-point scale ranging from 1 (not satisfied) to 5 (very satisfied). Only the 8 items referred to the device will be evaluated from participants and the whole 12 items from the therapists to measure user satisfaction with the ABLE Exoskeleton after the training program experience

    Time frame: After 12 months post-training

Secondary outcomes

  1. Time spent upright and time spent walking

    In each gait training session, the time spent upright (in minutes) and the time spent walking (in minutes) with the device will be automatically measured and registered by the device

    Time frame: At session 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10

  2. Number of steps walked

    In each gait training session, the number of steps taken (step count) with the device will be automatically measured and registered by the device

    Time frame: At session 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10

  3. Distance walked

    In each gait training session, the distance walked (in meters) with the device will be automatically measured and registered by the device

    Time frame: At session 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10

07

Study locations

1 site
  • Fundación Esclerosis Múltiple Madrid (FEMM)
    Madrid, Madrid 28029, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in May 2026, 13 months.

Of 874 interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 10, 2025
StartActual
Apr 7, 2025
Primary completionActual
May 29, 2026
CompletionActual
May 29, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06921551
Lead sponsor
ABLE Human Motion S.L.
Collaborators
Fundación Esclerosis Múltiple Madrid (FEMM)
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Apr 7, 2025
Primary completion
May 29, 2026
Completion
May 29, 2026
Last update
Jun 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion